ELOCTA 2000 IU powder and solvent for solution for injection
Authorisation EU/1/15/1046/006 · Swedish Orphan Biovitrum AB
- Licence holder
- Swedish Orphan Biovitrum AB (all products →)
- Active substance
- Efmoroctocog alfa
- Dosage form
- Powder and solvent for solution for injection
- Route of administration
- Intravenous use
- ATC codes
- B02BD, B02BD02
- First authorised
- 19/11/2015
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Full application (Article 8(3) of Directive No 2001/83/EC)
Efmoroctocog alfa: supply and approvals
8 authorised products on the HPRA list contain Efmoroctocog alfa. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 19 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 19 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 19 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 1046. It has been authorised for 11 years (since 19 November 2015). The HPRA list does not say whether it is on sale.
Other medicines with Efmoroctocog alfa in Ireland
7 other products on the HPRA list contain Efmoroctocog alfa, from 2 licence holders; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| ELOCTA 1000 IU powder and solvent for solution for injection | Swedish Orphan Biovitrum AB | Centralised EU authorisation | Not stated |
| ELOCTA 1500 IU powder and solvent for solution for injection | Swedish Orphan Biovitrum AB | Centralised EU authorisation | Not stated |
| ELOCTA 250 IU powder and solvent for solution for injection | Swedish Orphan Biovitrum AB | Centralised EU authorisation | Not stated |
| ELOCTA 3000 IU powder and solvent for solution for injection | Swedish Orphan Biovitrum AB | Centralised EU authorisation | Not stated |
| ELOCTA 4000 IU powder and solvent for solution for injection | Swedish Orphan Biovitrum AB(publ) | Centralised EU authorisation | Not stated |
| ELOCTA 500 IU powder and solvent for solution for injection | Swedish Orphan Biovitrum AB | Centralised EU authorisation | Not stated |
| ELOCTA 750 IU powder and solvent for solution for injection | Swedish Orphan Biovitrum AB | Centralised EU authorisation | Not stated |
Other substances in ATC group B02BD
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 40 other active substances share the group B02BD with this product:
Octocog alfa (13) · Simoctocog alfa (11) · Recombinant coagulation fviii (octocog alfa) (9) · Human coagulation factor viii (9) · Lonoctocog alfa (7) · Nonacog alfa (6) · Turoctocog alfa (6) · Eftrenonacog alfa (5) · TUROCTOCOG ALFA PEGOL (5) · Nonacog gamma (5) · Rurioctocog alfa pegol (4) · Rix-fp (4) · Recombinant antihemophilic factor (4) · Moroctocog alfa (4) · Von willebrand factor (4) · Factor ii activity (3) · Factor vii activity (3) · Factor x activity (3) · Factor ix activity (3) · Protein c activity (3) · and 20 more
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
Swedish Orphan Biovitrum AB holds 16 products on the HPRA list, with 5 different active substances; 0 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 20 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.